Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | GRK2 | P25098 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502888 | 0.97 | AKR1C1 (0.65) | AKR1C1HDAC4ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL17632673 | 0.95 | AKR1C1 (0.62) | AKR1C1HDAC4ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL671822 | 0.93 | AKR1C1 (0.53) | AKR1C1HDAC4ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4501046 | 0.85 | ALDH1A1 (0.48) | AKR1C1ALDH1A1GAASMN1; SMN2NPSR1 | |
| SCHEMBL29237470 | 0.85 | AKR1C1 (0.46) | AKR1C1HDAC4ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL11832779 | 0.85 | AKR1C1 (0.46) | AKR1C1HDAC4ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL30967898 | 0.85 | AKR1C1 (0.46) | AKR1C1HDAC4ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL14332444 | 0.85 | AKT1 (0.46) | AKR1C1ALDH1A1GAASMN1; SMN2NPSR1 | |
| SCHEMBL14737934 | 0.85 | LMNA (0.48) | AKR1C1HDAC4ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL30217007 | 0.84 | AKR1C1 (0.49) | AKR1C1HDAC4ALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028336-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4573096-A1 | INHIBITORS OF MYELOPEROXIDASE | Astrazeneca AB (SE) | 2025-06-25 | — | — | EP | disclosed |
| EP-4558501-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119894896-A | Inhibitors of green peroxidase | 阿斯利康(瑞典)有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2025024030-A2 | MOLECULAR GLUES TARGETING A TRANSCRIPTIONAL REGULATOR OF ABERRANT METABOLIC STATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20240166642-A1 | INHIBITORS OF MYELOPEROXIDASE | ASTRAZENECA AB (SE) | 2024-05-23 | — | — | US | disclosed |
| WO-2024038131-A1 | INHIBITORS OF MYELOPEROXIDASE | ASTRAZENECA AB (SE) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024020034-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020034-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-3814331-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | Phenex-FXR GmbH (DE) | 2021-05-05 | — | — | EP | disclosed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | AKR1C1 3661/4885HDAC4 1369/4885ALDH1A1 2026/4885 |
| US-20260028336-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | AKR1C1 1385/4885HDAC4 4082/4885ALDH1A1 3804/4885 |
| US-20240166642-A1 | INHIBITORS OF MYELOPEROXIDASE | MPO, XDH, EPX | AKR1C1 1339/4885HDAC4 1494/4885ALDH1A1 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.